Compositions and methods for the diagnosis and treatment of tumor
AssigneeGenentech, Inc.
InventorsMark Dennis, Bonnee Rubinfeld, Paul Polakis
Life of this patent
Estimating the term…
Abstract
The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
Claims6
A method of inhibiting the growth of a cell that expresses a TAT211 polypeptide comprising the amino acid sequence of SEQ ID NO:2 or an extracellular domain thereof, said method comprising contacting said cell with an antibody comprising:
- (a) a CDR-L1 sequence of SEQ ID NO:
- 21;
- (b) a CDR-L2 sequence of SEQ ID NO:
- 35;
- (c) a CDR-L3 sequence of SEQ ID NO:
- 39;
- (d) a CDR-H1 sequence of SEQ ID NO:
- 42;
- (e) a CDR-H2 sequence of SEQ ID NO:
- 46;
- and
- (f) a CDR-H3 sequence of SEQ ID NO:
- 61;
- wherein the binding of said antibody to said TAT211 polypeptide causes an inhibition of growth of said cell.
A method of therapeutically treating a mammal having a cancerous tumor comprising cells that express a TAT211 polypeptide comprising the amino acid sequence of SEQ ID NO:2 or an extracellular domain thereof, said method comprising administering to said mammal a therapeutically effective amount of an antibody comprising:
- (a) a CDR-L1 sequence of SEQ ID NO:
- 21;
- (b) a CDR-L2 sequence of SEQ ID NO:
- 35;
- (c) a CDR-L3 sequence of SEQ ID NO:
- 39;
- (d) a CDR-H1 sequence of SEQ ID NO:
- 42;
- (e) a CDR-H2 sequence of SEQ ID NO:
- 46;
- and
- (f) a CDR-H3 sequence of SEQ ID NO:
- 61;
- thereby effectively treating said mammal.
Dependencies are inferred from the claim text.